Healthcare >> CEO Interviews >> November 17, 2008
JOHN KOLLINS, Chief Executive Officer of OXiGENE, Inc., has nearly 20 years of
pharmaceutical and biotechnology industry experience, specifically in strategic
marketing, new product development and business development. Prior to joining
OXiGENE, Mr. Kollins had been an independent consultant since February 2005. His
clients included GRT Capital Partners, LLC's health care fund, GRT Health Care,
LP, Entelos, Inc., CovX and other private and publicly held biopharmaceutical
companies. From October 2004 until February 2005, he was the Chief Business
Officer at CovX Research LLC, a privately held biopharmaceutical company, of San
Diego, California. Mr. Kollins served as an advisor to CovX and chaired CovX's
external advisory board from 2005 until the sale of the company to Pfizer,
announced in December 2007. From January 2003 until January 2004, he served as
the Vice President, Business Development at Renovis, Inc., a biopharmaceutical
company located in South San Francisco, California, and was a consultant to
Renovis from January 2004 through October 2004. He started his career in the
biopharmaceutical industry in 1989 as a Product Manager with Immunex Corporation
and subsequently served in marketing and business development roles at Elan
Pharmaceuticals, Inc., and Athena Neurosciences, Inc. (acquired by Elan), as
well as at SurroMed, Inc., where he served as Vice President, Business
Development. Mr. Kollins graduated from Duke University with a BSE (Mechanical
Engineering and Materials Science) degree, magna cum laude, and earned an MBA
with honors from the University of Virginia's Darden Graduate School of
Business. Profile
Mr. Kollins: OXiGENE is a biopharmaceutical company that's focused on developing
a new class of drugs called vascular
